Sorrento Therapeutics, Inc. (SRNE), Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer They have so much going on, will we break the downtrend today?! 🤞 #Investment